Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Vigil Neuroscience Inc
VIGL
Healthcare
Biotechnology
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company, which is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based...
therapies to improve the lives of patients and their families. Its lead clinical candidate, iluzanebart, is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The Company is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:VIGL)
New Post
View:
Posts & Comments
Threaded Posts
(187)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on May 22, 2025 8:49am
Still holding this stock.BUY
Because it's being bought out today for a big amount ofcash and shares
(10)
•••
MikeTester
X
Post by
MikeTester
on Jan 23, 2025 8:45pm
Vigil Neuroscience (NASDAQ:VIGL): A Precision Approach to Ne
Looks like a promising play in the neuro space. VIGL's TREM2 agonist approach for rare neurodeg diseases is intriguing. Phase 2 IGNITE trial data looking solid with clear target engagement. $51
...more
BioVaxys & Adiverna Enter Collaboration to Develop Companion Animals Vaccines
posted Mar 10, 2026 9:00am by
BioVaxys Technology Corp.
-
|
“We are very excited to be working with Adiverna to develop what could be the world’s first mRNA veterinary vaccine. We believe the clinically proven advantages of the DPX platform formulated with Adiverna’s AI-designed mRNA sequences will provide for a superior product, adds Kovan. “With demonstrated in vivo proof of concept of DPX mRNA formulations, this ‘proof of product’ will further our partnering discussions utilizing DPX mRNA formulations in human therapeutic applications.” ...read more
(187)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jan 23, 2025 10:42am
Buy buddy buy because it's taking off this morning.
So good luck to all of you shareholders.
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 3:36pm
Vigil Neuroscience, Inc. (VIGL): A Promising Biotech Poised
https://beyondspx.com/2024/08/03/vigil-neuroscience-inc-vigl-a-promising-biotech-poised-to-revolutionize-neurodegenerative-disease-treatment/
(1)
•••
Garanga
X
Post by
Garanga
on Jul 05, 2024 12:57am
Going to $5+ easily
Next week.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Freegold Ventures reports results from six additional drill holes at its Golden Summit project
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
Team spotlight: Q+A: Charlene Duffett, Viridian Metals exploration manager
Podcasts